Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Pagel

Showing results (191-200 of 245) with videos related to

Pageof 25
Sort By:
Haematologica|December 23, 2021
Phase Ib dose-escalation study of the selective, non-covalent, reversible Bruton's tyrosine kinase inhibitor vecabrutinib in B-cell malignanciesJohn N Allan, Javier Pinilla-Ibarz, Douglas E Gladstone, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|July 23, 2013
Specific features identify patients with relapsed or refractory mantle cell lymphoma benefitting from autologous hematopoietic cell transplantationRyan D Cassaday, Katherine A Guthrie, Elizabeth L Budde, et al.
British Journal of Haematology|October 13, 2015
High-dose CD20-targeted radioimmunotherapy-based autologous transplantation improves outcomes for persistent mantle cell lymphomaRyan D Cassaday, Philip A Stevenson, Theodore A Gooley, et al.
The New England Journal of Medicine|December 8, 2015
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic LeukemiaAndrew W Roberts, Matthew S Davids, John M Pagel, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|August 6, 2010
Conditioning with treosulfan and fludarabine followed by allogeneic hematopoietic cell transplantation for high-risk hematologic malignanciesEneida R Nemecek, Katherine A Guthrie, Mohamed L Sorror, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 7, 2021
Ibrutinib Plus Venetoclax for First-Line Treatment of Chronic Lymphocytic Leukemia: Primary Analysis Results From the Minimal Residual Disease Cohort of the Randomized Phase II CAPTIVATE StudyWilliam G Wierda, John N Allan, Tanya Siddiqi, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 9, 2015
Maintenance rituximab after autologous stem cell transplantation in patients with mantle cell lymphomaS A Graf, P A Stevenson, L A Holmberg, et al.
Bone Marrow Transplantation|July 26, 2020
<sup>90</sup>Y-labeled anti-CD45 antibody allogeneic hematopoietic cell transplantation for high-risk multiple myelomaSherilyn A Tuazon, Brenda M Sandmaier, Theodore A Gooley, et al.
Transplantation and Cellular Therapy|September 27, 2020
Yttrium-90 Anti-CD45 Immunotherapy Followed by Autologous Hematopoietic Cell Transplantation for Relapsed or Refractory LymphomaSherilyn A Tuazon, Ryan D Cassaday, Theodore A Gooley, et al.
British Journal of Haematology|July 9, 2013
A model for prediction of FLT3-ITD and NPM1 (without FLT3-ITD) positivity in patients with newly diagnosed acute myeloid leukaemiaFabiana Ostronoff, Megan Othus, Hagop M Kantarjian, et al.
Pageof 25

Showing results (191-200 of 245) with videos related to

Sort By:
Pageof 25
Haematologica|December 23, 2021
Phase Ib dose-escalation study of the selective, non-covalent, reversible Bruton's tyrosine kinase inhibitor vecabrutinib in B-cell malignanciesJohn N Allan, Javier Pinilla-Ibarz, Douglas E Gladstone, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|July 23, 2013
Specific features identify patients with relapsed or refractory mantle cell lymphoma benefitting from autologous hematopoietic cell transplantationRyan D Cassaday, Katherine A Guthrie, Elizabeth L Budde, et al.
British Journal of Haematology|October 13, 2015
High-dose CD20-targeted radioimmunotherapy-based autologous transplantation improves outcomes for persistent mantle cell lymphomaRyan D Cassaday, Philip A Stevenson, Theodore A Gooley, et al.
The New England Journal of Medicine|December 8, 2015
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic LeukemiaAndrew W Roberts, Matthew S Davids, John M Pagel, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|August 6, 2010
Conditioning with treosulfan and fludarabine followed by allogeneic hematopoietic cell transplantation for high-risk hematologic malignanciesEneida R Nemecek, Katherine A Guthrie, Mohamed L Sorror, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 7, 2021
Ibrutinib Plus Venetoclax for First-Line Treatment of Chronic Lymphocytic Leukemia: Primary Analysis Results From the Minimal Residual Disease Cohort of the Randomized Phase II CAPTIVATE StudyWilliam G Wierda, John N Allan, Tanya Siddiqi, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 9, 2015
Maintenance rituximab after autologous stem cell transplantation in patients with mantle cell lymphomaS A Graf, P A Stevenson, L A Holmberg, et al.
Bone Marrow Transplantation|July 26, 2020
<sup>90</sup>Y-labeled anti-CD45 antibody allogeneic hematopoietic cell transplantation for high-risk multiple myelomaSherilyn A Tuazon, Brenda M Sandmaier, Theodore A Gooley, et al.
Transplantation and Cellular Therapy|September 27, 2020
Yttrium-90 Anti-CD45 Immunotherapy Followed by Autologous Hematopoietic Cell Transplantation for Relapsed or Refractory LymphomaSherilyn A Tuazon, Ryan D Cassaday, Theodore A Gooley, et al.
British Journal of Haematology|July 9, 2013
A model for prediction of FLT3-ITD and NPM1 (without FLT3-ITD) positivity in patients with newly diagnosed acute myeloid leukaemiaFabiana Ostronoff, Megan Othus, Hagop M Kantarjian, et al.
Pageof 25